S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China

Reviva Pharmaceuticals (RVPH) Competitors

$3.02
-0.18 (-5.63%)
(As of 04/18/2024 ET)

RVPH vs. DMAC, CNTB, ANIX, IOBT, RZLT, CELU, ALLK, CLSD, MCRB, and IFRX

Should you be buying Reviva Pharmaceuticals stock or one of its competitors? The main competitors of Reviva Pharmaceuticals include DiaMedica Therapeutics (DMAC), Connect Biopharma (CNTB), Anixa Biosciences (ANIX), IO Biotech (IOBT), Rezolute (RZLT), Celularity (CELU), Allakos (ALLK), Clearside Biomedical (CLSD), Seres Therapeutics (MCRB), and InflaRx (IFRX). These companies are all part of the "pharmaceutical preparations" industry.

Reviva Pharmaceuticals vs.

DiaMedica Therapeutics (NASDAQ:DMAC) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.

Reviva Pharmaceuticals' return on equity of -40.07% beat DiaMedica Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
DiaMedica TherapeuticsN/A -40.07% -37.90%
Reviva Pharmaceuticals N/A -1,344.46%-307.04%

10.1% of DiaMedica Therapeutics shares are owned by institutional investors. Comparatively, 63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. 7.2% of DiaMedica Therapeutics shares are owned by insiders. Comparatively, 31.8% of Reviva Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DiaMedica TherapeuticsN/AN/A-$19.38M-$0.62-4.02
Reviva PharmaceuticalsN/AN/A-$24.34M-$1.64-1.84

DiaMedica Therapeutics has a beta of 1.69, indicating that its stock price is 69% more volatile than the S&P 500. Comparatively, Reviva Pharmaceuticals has a beta of -0.02, indicating that its stock price is 102% less volatile than the S&P 500.

DiaMedica Therapeutics received 74 more outperform votes than Reviva Pharmaceuticals when rated by MarketBeat users. However, 88.24% of users gave Reviva Pharmaceuticals an outperform vote while only 61.81% of users gave DiaMedica Therapeutics an outperform vote.

CompanyUnderperformOutperform
DiaMedica TherapeuticsOutperform Votes
89
61.81%
Underperform Votes
55
38.19%
Reviva PharmaceuticalsOutperform Votes
15
88.24%
Underperform Votes
2
11.76%

DiaMedica Therapeutics presently has a consensus target price of $7.00, indicating a potential upside of 181.12%. Reviva Pharmaceuticals has a consensus target price of $16.75, indicating a potential upside of 454.64%. Given DiaMedica Therapeutics' higher possible upside, analysts plainly believe Reviva Pharmaceuticals is more favorable than DiaMedica Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DiaMedica Therapeutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Reviva Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Reviva Pharmaceuticals had 10 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 11 mentions for Reviva Pharmaceuticals and 1 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 0.31 beat Reviva Pharmaceuticals' score of -0.50 indicating that Reviva Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
DiaMedica Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Negative
Reviva Pharmaceuticals
1 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Reviva Pharmaceuticals beats DiaMedica Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Reviva Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for RVPH and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RVPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RVPH vs. The Competition

MetricReviva PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$84.32M$6.45B$4.77B$7.44B
Dividend YieldN/A2.97%2.99%4.00%
P/E Ratio-1.8417.03253.1519.04
Price / SalesN/A330.892,416.1485.85
Price / CashN/A20.9447.2935.12
Price / Book5.035.484.594.19
Net Income-$24.34M$147.46M$104.50M$214.15M
7 Day Performance-20.32%-7.92%-5.34%-4.90%
1 Month Performance-1.95%-7.80%-4.81%-3.48%
1 Year Performance-38.74%-3.68%8.51%3.84%

Reviva Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DMAC
DiaMedica Therapeutics
0.9665 of 5 stars
$2.71
-2.5%
$7.00
+158.3%
+62.5%$102.87MN/A-4.3718News Coverage
CNTB
Connect Biopharma
2.7441 of 5 stars
$1.87
+3.9%
$6.00
+220.9%
+42.2%$102.98MN/A0.00100Analyst Report
Short Interest ↑
News Coverage
Gap Up
ANIX
Anixa Biosciences
2.6366 of 5 stars
$3.25
+2.5%
$12.00
+269.2%
-32.4%$103.68M$210,000.00-9.564Positive News
IOBT
IO Biotech
3.2795 of 5 stars
$1.58
+2.6%
$8.33
+427.4%
-20.0%$104.09MN/A-0.7368News Coverage
Gap Up
RZLT
Rezolute
3.1185 of 5 stars
$2.50
-1.2%
$8.50
+240.0%
+58.0%$99.05MN/A-2.2757Analyst Report
News Coverage
Positive News
Gap Up
CELU
Celularity
0 of 5 stars
$5.40
-2.5%
N/A-55.3%$104.65M$17.98M0.00225Short Interest ↑
Gap Down
ALLK
Allakos
4.0673 of 5 stars
$1.20
+6.2%
$1.83
+52.8%
-74.1%$105.44MN/A-0.56131
CLSD
Clearside Biomedical
2.9414 of 5 stars
$1.29
flat
$4.75
+268.2%
+15.6%$96.39M$8.23M-2.4330Gap Down
MCRB
Seres Therapeutics
3.4823 of 5 stars
$0.71
-2.7%
$6.67
+839.8%
-90.4%$107.13M$126.32M-0.79233
IFRX
InflaRx
2.5697 of 5 stars
$1.62
+6.6%
$13.50
+733.3%
-70.0%$95.39M$70,000.00-1.8862

Related Companies and Tools

This page (NASDAQ:RVPH) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners